OncRef
Skip to newsletter content
|
RCCMay 2026
0:00 / 2:31
Renal Cell Carcinoma — Monthly Compass
May 01–31, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in renal cell carcinoma this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
renal cell carcinoma updates
Key Highlights
Key Highlights
  • Key Clinical Development Updates
    • Merck reported that FDA is reviewing a Priority Review supplement for WELIREG (belzutifan) plus KEYTRUDA in adjuvant clear cell RCC with a PDUFA date of June 19, 2026, supported by LITESPARK‑022, with U.S. review ongoing.
    • FDA reviews are also ongoing in the U.S. (and in Japan for the combination) for WELIREG plus LENVIMA (lenvatinib) in previously treated advanced RCC with a PDUFA date of October 4, 2026, supported by LITESPARK‑011.
  • Important Clinical Trial Publications
    • The phase 2 randomized RADICAL trial (Alliance A031801) reported that radium‑223 plus cabozantinib did not improve SSE‑free survival versus cabozantinib alone in RCC with bone metastases, although an overall survival separation signal emerged.
  • Key Conference Updates
    • At ASCO 2026, RAMPART showed that adjuvant durvalumab monotherapy did not significantly improve disease‑free survival, sharpening focus on patient selection and combination strategies in the perioperative setting.
    • ASCO 2026 presentations highlighted CAIX PET–selected delivery of 177Lu‑girentuximab (TLX250‑Tx) in LUTEON as a targeted beta‑radiation approach and demonstrated manageable safety for the GCN2 inhibitor HC‑7366 alone or with belzutifan in advanced RCC.
  • Emerging Themes & Macro-Trends
    • RCC development is diversifying beyond classic VEGF/IO paradigms toward radiotherapeutics—particularly CAIX‑directed beta‑emitters—and stress‑pathway (GCN2) plus HIF‑2α combinations aimed at overcoming post‑PD‑1 resistance with differentiated tolerability.
    • Strategic priorities emphasized combining CAIX‑RLT with PD‑1 or HIF‑2α backbones, embedding ctDNA/MRD partnerships in perioperative trials, and investing in stress‑pathway (GCN2) combinations to address post‑PD‑1 resistance.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • There are no press releases between 2026-05-01 and 2026-05-31 about renal cell carcinoma.
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • Merck reported in its Q1 2026 Form 10‑Q that FDA is reviewing two RCC supplements: WELIREG (belzutifan) plus KEYTRUDA/KEYTRUDA QLEX for adjuvant clear cell RCC under Priority Review with a PDUFA date of June 19, 2026, and WELIREG plus LENVIMA (lenvatinib) for previously treated advanced RCC with a PDUFA date of October 4, 2026. The company noted these submissions are supported by LITESPARK‑022 (adjuvant) and LITESPARK‑011 (previously treated) and that U.S. (and Japan for WELIREG+LENVIMA) reviews are ongoing. (merck.com) ¹ (read more)
Conference
Major Conference Updates
Conference Information
  • American Society of Clinical Oncology (ASCO) Annual Meeting 2026; Chicago, Illinois; May 29–June 2, 2026. (read more)
  • RCC takeaways: perioperative immunotherapy strategies were recalibrated by new adjuvant data; MRD/ctDNA analyses gained practical traction; and radiotherapeutics plus stress‑pathway targets signaled diversification beyond classic VEGF/IO paradigms. (read more)
  • Theme 1: Perioperative IO Recalibration + MRD Integration
    • Significance: Adjuvant immunotherapy beyond pembrolizumab remains unsettled; RAMPART showed durvalumab monotherapy did not significantly improve DFS, sharpening focus on patient selection and combination strategies. (read more)
    • Mechanism insights / clinical impact: Dual checkpoint (durvalumab+tremelimumab) preferentially benefitted highest‑risk subsets (e.g., high Leibovich/M1 NED), suggesting intensified T‑cell priming may be needed in biologically adverse disease; concurrent KEYNOTE‑564 ctDNA analysis underscored prognostic utility of MRD to refine who truly needs adjuvant therapy. (read more)
    • Patient populations affected: Resected intermediate/high‑risk ccRCC and M1 NED cohorts; global practice where adjuvant pembrolizumab is available but overtreatment risk is a concern. (read more)
  • Theme 2: Radiotherapeutics Advance Into Randomized RCC
    • Significance: Bone‑targeted alpha therapy and CAIX‑directed beta‑emitters are moving from concept to comparative testing, broadening options for patients with metastatic disease and offering organ‑sparing, tumor‑selective approaches. (read more)
    • Mechanism insights / clinical impact: RADICAL (radium‑223 + cabozantinib) did not improve SSE‑free survival vs cabozantinib alone, though an OS separation signal emerged—highlighting endpoint selection and biology of alpha‑emitters in RCC bone disease; in parallel, LUTEON (TLX250‑Tx, 177Lu‑girentuximab) operationalizes CAIX PET selection to deliver targeted beta radiation, potentially improving disease control with manageable toxicity. (read more)
    • Patient populations affected: Metastatic ccRCC with bone metastases (RADICAL) and CAIX‑positive relapsed/refractory ccRCC candidates for radioligand therapy (LUTEON). (read more)
  • Theme 3: Stress‑Pathway Targeting and HIF‑2α–Based Combinations
    • Significance: Early clinical signals with GCN2 inhibition, alone and with belzutifan, point to a new resistance‑circumventing axis beyond VEGF/IO doublets in post‑PD‑1 settings. (read more)
    • Mechanism insights / clinical impact: HC‑7366 (GCN2 kinase inhibitor) ± belzutifan (HIF‑2α inhibitor) showed manageable safety; mechanistically, nutrient‑stress sensing (GCN2) plus hypoxia signaling (HIF‑2α) may suppress tumor adaptation while avoiding overlapping VEGF‑TKI toxicities—supporting rational, biomarker‑hypothesis–driven combinations. (read more)
    • Patient populations affected: Locally advanced/metastatic RCC progressing after checkpoint inhibitors; settings where non‑VEGF combinations with improved tolerability could maintain dose intensity and access. (read more)
  • Significance
    • Expected clinical or translational readouts: Mature OS from RADICAL and additional MRD/ctDNA correlations in adjuvant RCC; early LUTEON part‑selection updates and safety. (ascopubs.org) (read more)
    • Regulatory or policy implications: No immediate label shifts; adjuvant pembrolizumab remains the default while RAMPART tempers enthusiasm for single‑agent alternatives; ctDNA remains investigational for decision‑making. (read more)
    • Potential shifts in standard of care: Positive CAIX‑RLT phase 3 outcomes could introduce a biomarker‑selected radioligand line; validated MRD could enable de‑escalation/escalation frameworks post‑nephrectomy. (read more)
    • Strategic implications: Prioritize CAIX‑RLT combinations with PD‑1 or HIF‑2α backbones; build ctDNA/MRD partnerships in perioperative trials; invest in stress‑pathway (GCN2) combos to address post‑PD‑1 resistance with differentiated safety. (read more)
Publications Related to Approved Drugs
Unknown Drug
There are no new publication updates during the 2026-05-01 to 2026-05-31 for renal cell carcinoma.
New Publications Related to Drugs in Clinical Trial Development
There are no new publication updates during the 2026-05-01 to 2026-05-31 for renal cell carcinoma.
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in renal cell carcinoma updated from 2026-05-01 to 2026-05-31:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation-------
Not Yet Recruiting319---13
Recruiting171115-2146
Available-------
Approved for Marketing-------
Active, Not Recruiting8512-7-32
Completed1-----1
Total291736-9192
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Belzutifan NCT04846920 COMPLETED A Phase 1, Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) 2026-04-11
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Cabozantinib, Cabozantinib S-malate NCT02867592 ACTIVE_NOT_RECRUITING Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors 2026-06-27
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
No phase 3 trials completing within the next three months.
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
No phase 4 trials completing within the next three months.
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.